Loading...
Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $1.5M Total Trade · DGFT Verified
BDH Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.5M across 2 products in 2 therapeutic categories. Based on 30 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Celecoxib ($1.1M), Zinc ($350.0K), .
BDH Healthcare Private Limited, established on July 3, 2013, is a private unlisted pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24233MH2013PTC245156. Its authorized capital stands at ₹5.00 million, with a paid-up capital of ₹4.97 million. The registered office is located at Nair Baug, Second Floor, Akurli Road, Kandivli East, Mumbai, Maharashtra, 400101. BDH Healthcare specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, focusing on drug formulation and development.
BDH Healthcare Private Limited operates across 2 therapeutic categories, with Analgesics & Antipyretics (76.7%), Vitamins & Supplements (23.3%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Analgesics & Antipyretics
1 products · 76.7% · $1.1M
Vitamins & Supplements
1 products · 23.3% · $350.0K
BDH Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Celecoxib | Analgesics & Antipyretics | $1.1M | 23 | 0.9% | 6 |
| 2 | Zinc |
Headquarters, ownership, manufacturing facilities, and key leadership
BDH Healthcare Private Limited, established on July 3, 2013, is a private unlisted pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24233MH2013PTC245156. Its authorized capital stands at ₹5.00 million, with a paid-up capital of ₹4.97 million. The registered office is located at Nair Baug, Second Floor, Akurli Road, Kandivli East, Mumbai, Maharashtra, 400101. BDH Healthcare specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, focusing on drug formulation and development.
BDH Healthcare operates manufacturing facilities in Daman, Daman and Diu, India. The company is classified as a micro enterprise under the MSME category for the financial year 2024-25. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.
| $350.0K |
| 7 |
0.4% |
| 12 |
BDH Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.5M. The top category is Analgesics & Antipyretics (76.7% of portfolio), followed by Vitamins & Supplements (23.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for BDH Healthcare Private Limited.
Request DemoThe company's leadership comprises two directors:
Additionally, Ms. Jayashree Nair serves as the Chairperson and Managing Director of BDH Industries Limited, a related entity.
Regulated market presence, emerging market penetration, and geographic strategy
BDH Healthcare's export activities are primarily focused on finished pharmaceutical formulations, with a total export value of $1.5 million USD across 30 shipments. The company's product portfolio includes two products across two therapeutic categories:
The company does not hold a market leader position in any of these categories. The portfolio is highly concentrated, with the top 5 products accounting for 100% of exports.
BDH Healthcare's export data does not specify its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's focus appears to be on established markets, with no evidence of WHO prequalification or similar certifications that would facilitate access to these regions.
The company's export strategy is highly concentrated, with a portfolio consisting solely of two products across two therapeutic categories. This lack of diversification may expose BDH Healthcare to risks associated with market fluctuations and regulatory changes in its target markets. A more diversified product portfolio and broader geographic reach could mitigate these risks and enhance the company's strategic position.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
There is no publicly available information regarding BDH Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. This lack of transparency may indicate limited engagement with the U.S. market or a strategic decision to focus on other regions.
BDH Healthcare's export data does not indicate WHO prequalification or EU Good Manufacturing Practice (GMP) certifications. These certifications are essential for accessing certain international markets and ensuring compliance with global quality standards. The absence of such certifications may limit the company's ability to expand its presence in regulated markets.
BDH Healthcare holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, as evidenced by its incorporation under the Ministry of Corporate Affairs. The company has also obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities.
There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to BDH Healthcare. This suggests that the company has maintained compliance with regulatory standards in its operations.
Market share comparison, key differentiators, and strategic analysis
BDH Healthcare operates in the pharmaceutical industry, exporting finished formulations in categories such as analgesics, antipyretics, vitamins, and supplements. The company's top products, Celecoxib and Zinc, are in direct competition with other manufacturers in these therapeutic areas. However, without specific market share data for these products, a detailed competitive analysis is challenging.
BDH Healthcare's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, allows it to cater to a broad spectrum of therapeutic needs. The company's specialization in drug formulation and development positions it to adapt to evolving market demands and regulatory requirements.
BDH Healthcare's current strategic direction appears to be centered on the export of finished pharmaceutical formulations, with a concentrated product portfolio. The company may benefit from diversifying its product range and exploring new therapeutic areas to enhance its market presence and reduce dependency on a limited number of products.
Track record assessment, certifications to verify, and pre-order checks
BDH Healthcare's export volume of $1.5 million USD across 30 shipments indicates a consistent supply capability. The company's focus on finished formulations suggests a commitment to quality and compliance with international standards. However, the lack of diversification in its product portfolio may impact its ability to meet a broader range of market demands.
Importers should verify the following certifications to ensure product quality and regulatory compliance:
These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.
Importers should undertake the following steps to ensure a thorough evaluation of BDH Healthcare:
Red flags to watch for include expired or invalid certifications, inconsistent financial records, unresolved regulatory issues, and lack of transparency in supply chain practices.
BDH Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Celecoxib ($1.1M), Zinc ($350.0K). Total export value is $1.5M.
BDH Healthcare Private Limited's total pharmaceutical export value is $1.5M, based on 30 verified shipments recorded in Indian Customs (DGFT) data.
BDH Healthcare Private Limited exports across 2 therapeutic categories. The largest are Analgesics & Antipyretics (76.7%, 1 products), Vitamins & Supplements (23.3%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
2 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.